Abstract
Drug resistance, both intrinsic resistance present in many previously untreated patients and acquired resistance, which frequently develops in patients who respond to therapy, is a major clinical problem in ovarian cancer which limits the overall effectiveness of most chemotherapeutic agents. An understanding of the mechanisms responsible for resistance in ovarian cancer would likely facilitate pharmacologic attempts to reverse or modify this resistance and thereby increase the efficacy of these drugs. Intraperitoneal chemotherapy in ovarian cancer is an attempt to overcome drug resistance which results from the inability to achieve cytotoxic drug levels in the peritoneal cavity following either oral or intravenous administration of the same drugs. The pharmacologic rationale for intraperitoneal administration of anticancer agents has been presented elsewhere in this monograph by Collins et al.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Dedrick RL, Myers CE, Bugnay PM, DeVita VT: Pharmacokinetic rationale for peritoneal drug administration in treatment of ovarian cancer. Cancer Treat Rep (62): 1–11, 1978.
Jones RB, Collins JM, Myers CE, Brooks AE, Hubbard SM, Ballow JW, Brennan MF, Dedrick RL, DeVita VT: High-volume intraperitoneal chemotherapy with methotrexate in patients with cancer. Cancer Res (41): 55–59, 1981.
Speyer JL, Collins JM, Dedrick RL, Brennan MF, Londer H, DeVita VT, Myers CM: Phase I and pharmacologic studies of 5-Fluorouracil administered intraperitoneally. Cancer Res (40): 567–572, 1980.
Ozols RF, Young RC, Speyer JL, Sugarbaker PH, Greene R, Jenkins J, Myers CE: Phase I and pharmacologic studies of Adriamycin administered intraperitoneally to patients with ovarian cancer. Cancer Res (42): 4265–4269, 1982.
Ozols RF, Speyer JL, Jenkins J,Myers CE: Phase II trial of 5-Fluorouracil administered intraperitoneally to patients with refractory ovarian cancer. Cancer Treat Rep (in press) 1984.
Jenkins J, Sugarbaker PH, Gianola FJ, Myers CE: Technical considerations in the use of intraperitoneal chemotherapy administered by Tenckhoff catheter. Surgery (154): 858–864, 1982.
Ozols RF, Grotzinger KR, Fisher RI, Myers CE, Young RC: Kinetic characterization and response to chemotherapy in a transplantable murine ovarian cancer. Cancer Res (39): 3202–3208, 1979.
Ozols RF, Locker GY, Doroshow JH, Grotzinger KR, Myers CE, Young RC: Pharmacokinetics of Adriamycin and tissue penetration in murine ovarian cancer. Cancer Res (30): 3209–3214, 1979.
Ozols RF, Willson JKV, Grotzinger KR, Young RC: Cloning of human ovarian cancer cells in soft agar from malignant effusions and peritoneal washings. Cancer Res (40): 2743–2747, 1980.
Ozols RF, Willson JKV, Weltz MD, Grotzinger KR, Myers CE, Young RC: Inhibition of human ovarian cancer colony formation by Adriamycin and its major metabolites. Cancer Res (40): 4109–4112, 1980.
Hubbard SM, Barkes P, Young RC: Adriamycin therapy for advanced ovarian carcinoma recurrent after chemotherapy. Cancer Treat Rep (67): 1375–1377, 1978.
Ozols RF, Myers CE, Young RC: The potential role of anthracyclines in the intraperitoneal chemotherapy of ovarian cancer. In: Hansen HH (ed). Anthracyclines and Cancer Therapy. Excerpta Medica Amsterdam, 1983, 158–165.
Young RC, Howser DM, Myers CE, Ozols RF, Fisher RI, Wesley M, Chabner BA: Combination chemotherapy (CHEX-UP) with intraperitoneal maintenance in advanced ovarian adenocarcinoma. Proc Amer Soc Clin Oncol (22): 465, 1981.
Ozols RF, Corden BJ, Jacob J, Wesley MM, Ostchega Y, Young RC: Highdose cisplatin in hypertonic saline. Annals Int Med (100): 19–24, 1984.
Rogan AM, Hamilton TC, Young RC, Ozols RF: Pharmacologic modulation of Adriamycin resistance in ovarian cancer. In: Salmon S (ed). Proc IV Tumor Cloning Conf (in press) 1984.
Ozols RF, Rogan AM, Hamilton TC, Klecker R, Young RC: Verapamil plus Adriamycin in refractory ovarian cancer: design of a clinical trial on basis of reversal of Adriamycin resistance in human ovarian cancer cell lines. Proc Amer Assoc Cancer Res (in press) 1984.
Ozols RF, Green JA, Hamilton TC, Vistica DT, Young RC: Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines. In: Salmon S (ed). Proc IV Tumor Cloning Conf (in press) 1984.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1984 Martinus Nijhoff Publishers, Boston
About this chapter
Cite this chapter
Ozols, R.F., Young, R.C., Myers, C.E. (1984). Intraperitoneal Adriamycin and 5-Fluorouracil in Ovarian Cancer. In: Howell, S.B. (eds) Intra-Arterial and Intracavitary Cancer Chemotherapy. Developments in Oncology, vol 26. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-3843-7_17
Download citation
DOI: https://doi.org/10.1007/978-1-4613-3843-7_17
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-3845-1
Online ISBN: 978-1-4613-3843-7
eBook Packages: Springer Book Archive